Mitral valve and left ventricular features in malignant mitral valve prolapse. by Garbi, M et al.
Open access 
  1Garbi M, et al. Open Heart 2018;5:e000925. doi:10.1136/openhrt-2018-000925
To cite: Garbi M, Lancellotti P, 
Sheppard MN. Mitral valve and 
left ventricular features in 
malignant mitral valve prolapse. 
Open Heart 2018;5:e000925. 
doi:10.1136/
openhrt-2018-000925
Received 24 August 2018
Revised 4 September 2018
Accepted 26 September 2018
1King's Health Partners, King’s 
College Hospital NHS Foundation 
Trust, London, UK
2Department of Cardiology, 
GIGA Cardiovascular Sciences, 
University of Liège Hospital, 
Liège, Belgium
3Anthea Hospital, Gruppo Villa 
Maria Care and Research, Bari, 
Italy
4Cardiovascular Pathology Unit, 
St Georges Hospital Medical 
School, London, UK
Correspondence to
Dr Madalina Garbi;  madalina. 
garbi@ nhs. net
Mitral valve and left ventricular features 
in malignant mitral valve prolapse
Madalina Garbi,1 Patrizio Lancellotti,2,3 Mary N Sheppard4
Valvular heart disease
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
Key questions
What is already known about this subject?
 ► Mitral valve prolapse is a benign condition, however 
with occasional reports of sudden cardiac death or 
out-of-hospital cardiac arrest in the absence of se-
vere mitral regurgitation or coronary artery disease, 
suggesting the existence of a malignant form.
 ► Sudden cardiac death is rare in mitral valve pro-
lapse; however, the risk is twice as high as for the 
general population.
 ► Characterisation of malignant mitral valve prolapse 
is needed to underpin the selection of patients in 
need of implantable cardioverter defibrillator for pri-
mary prevention.
What does this study add?
 ► Our study demonstrates association of mitral valve 
prolapse–related sudden cardiac death with Barlow 
disease rather than fibroelastic deficiency or degen-
erative mitral valve disease in general.
 ► The association was independent of mitral regurgi-
tation severity, however related with the existence of 
left ventricular interstitial fibrosis and degeneration 
of myocytes suggestive of a distinct cardiomyopathy.
How might this impact on clinical practice?
 ► While further evidence is needed to underpin the 
selection of patients in need of implantable car-
dioverter defibrillator for primary prevention, our 
results narrow down the spectrum of high-risk 
characteristics to Barlow disease with associated 
cardiomyopathy.
 ► Additionally, our findings could guide further studies 
of myocardial fibrosis with cardiac magnetic reso-
nance, combining T1-mapping and late gadolinium 
enhancement for sudden death risk stratification in 
mitral valve prolapse.
AbstrAct
Objective Mitral valve prolapse is a benign condition, 
however with occasional reports of sudden cardiac death 
or out-of-hospital cardiac arrest in the absence of severe 
mitral regurgitation or coronary artery disease, suggesting 
the existence of a malignant form. The objective of 
our study was to contribute to the characterisation of 
malignant mitral valve prolapse.
Methods We performed a retrospective analysis of 
pathology findings in 68 consecutive cases of sudden 
cardiac death with mitral valve prolapse as lone abnormal 
finding, reported as cause of death.
Results All mitral valve prolapse sudden death cases had 
mitral valve characteristics of Barlow disease, with extensive 
bileaflet multisegmental prolapse and dilatation of the 
annulus. The majority of cases (80.9%) had microscopic 
left ventricular fibrosis with associated hypertrophy and 
degenerative features of the myocytes, and some cases 
(10.9%) had right ventricular fibrosis as well.
Conclusions Malignant mitral valve prolapse is Barlow 
disease. Sudden cardiac death in mitral valve prolapse is 
due to Barlow disease, which besides the typical mitral 
valve degeneration may comprise a distinct Barlow 
disease cardiomyopathy, as suggested by myocyte 
degeneration and bi-ventricular involvement.
IntROduCtIOn
Mitral valve prolapse (MVP) is usually a 
benign condition, however with sporadic 
reports of sudden cardiac death (SCD) or 
out-of-hospital cardiac arrest, often in the 
absence of significant mitral regurgitation,1–4 
suggesting the existence of a malignant 
form. MVP-related SCD has low incidence; 
however, the risk is twice as high as for the 
general population.5 The characterisation of 
a high-risk population in need of implantable 
cardioverter defibrillator (ICD) for primary 
prevention is difficult because SCD can occur 
in cases with no previous clinical diagnosis. 
A study of out-of-hospital cardiac arrest survi-
vors found bileaflet involvement in malignant 
MVP,6 and these patients had ICD-treated 
ventricular fibrillation recurrences.
Unexplained left ventricular systolic 
dysfunction, in the absence of severe mitral 
regurgitation or coronary artery disease, is 
reported occasionally7 8 and it was found to 
be an independent mortality risk factor in a 
community study of outcome of MVP.9
Our study aim was to contribute to the char-
acterisation of malignant MVP by reviewing 
the mitral valve and left ventricular pathology 
findings in MVP-related SCD.
MetHOds
We performed a retrospective analysis 
of pathology findings in 68 consecutive 
SCD cases with MVP reported as cause of 
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Figure 1 Barlow mitral valve with thickening and ballooning 
of the leaflets in between the chords and thickening and 
elongation of the chords.
Figure 2 Ventricular fibrosis in Barlow disease.
death. The pathology assessment of all cases had been 
performed for diagnostic purposes, as part of a clinical 
autopsy, with no preconceived research hypothesis, by 
the same expert cardiovascular pathologist (MNS), at 
the Cardiovascular Pathology Reference Centre of the 
St George’s Medical School in London. The assessment 
had next-of-kin consent and followed cardiac pathology 
guidelines10 and the methodology described by MNS.11
Results
Almost half of the SCD cases (48.5%) were younger than 
35 years old, with a mean age of 38 years (SD±15). There 
was marginal male predominance (51.7%).
Clinical information was available in 50 cases (73.5%), 
revealing lack of symptoms (n=30) and documented mild 
only mitral regurgitation (n=20). Six cases had relevant 
family history, comprising MVP with female predomi-
nance and SCD in three female relatives.
All 68 SCD cases had no evidence of coronary artery 
disease at autopsy.
In all cases, the mitral valve had extensive bileaflet 
multisegmental prolapse and dilatation of the annulus. 
The leaflets had pronounced permanent displacement 
into the left atrium (atrialisation) and thickening and 
ballooning in between the chords (figure 1). In all cases, 
there was severe tissue redundancy of the leaflets, with 
grade III prolapse.5 The chords were thickened and elon-
gated, but there was no chordal rupture. In conclusion, 
all cases had typical mitral valve characteristics of Barlow 
disease, suggesting SCD association with Barlow disease 
specifically, rather than with fibroelastic deficiency and 
rather than with degenerative mitral valve disease or MVP 
in general.
There was no associated tricuspid valve prolapse; the 
tricuspid valve was normal in all cases.
In only 17 cases (25%), there was hypertrophy with 
increased heart weight (>500 g) and left ventricular wall 
thickness (>15 mm).
The existence of MVP without chordal rupture 
prompted thorough assessment for myocardial fibrosis 
in all cases; this is because, in the absence of chordal 
rupture, based on pathology guidelines,10 MVP is a highly 
probable cause of the SCD only in the presence of asso-
ciated myocardial fibrosis. Macroscopic analysis found 
no evidence of ventricular wall fibrosis in any of the 68 
cases. However, microscopic analysis found ventricular 
fibrosis in the majority of cases (n=55, 80.9%), confined 
to the left ventricle in 49 cases (89.1%) and involving the 
right ventricle as well in six cases (10.9%). The fibrosis 
(figure 2) was focal, usually fine and interstitial within 
the inner wall, involving particularly the inner suben-
docardium, trabeculae and papillary muscles. In the 
left ventricle, within the inner third of the basal poste-
rior wall, the fibrosis became confluent, with extensive 
replacement fibrosis extending into the trabeculae and 
posteromedial papillary muscle. The fibrosis was never 
epicardial or diffuse throughout the wall. Because MVP 
with associated fibrosis is a highly probable but not certain 
cause of SCD based on pathology guidelines, histological 
analysis of the myocardium was also performed. Associ-
ated with the myocardial fibrosis, there was hypertrophy 
and degenerative features of the myocytes with focal cyto-
plasmic vacuolation (figure 3) suggestive of existence 
of a cardiomyopathy. There was no myocyte disarray to 
establish a diagnosis of hypertrophic cardiomyopathy, 
and there was no associated fatty infiltration to establish 
a diagnosis of arrhythmogenic cardiomyopathy. All cases 
had posterior left ventricular wall and posterior papillary 
muscle involvement. Twelve cases had lateral and anterior 
left ventricular wall involvement as well. Sixteen cases had 
midwall interventricular septum fibrosis, which became 
confluent with the basal posterior fibrosis. In the right 
ventricle, the fibrosis was usually subendocardial, with 
fine interstitial pattern in the posterior wall extending 
into the basal posterior left ventricular fibrosis. There 
was interventricular septum fibrosis in all cases with right 
ventricular involvement.
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Figure 3 Degenerated myocytes with cytoplasmic 
vacuolation but no disarray in Barlow disease.
The SCD cases with ventricular fibrosis had marked 
dilatation of the mitral valve annulus in the absence of left 
ventricular cavity dilatation, suggesting more advanced 
mitral valve degeneration, not necessarily associated with 
more severe mitral regurgitation, as 29% of cases had 
documented mild only mitral regurgitation.
dIsCussIOn
We report, to the best of our knowledge, the largest 
number of SCD cases with MVP as lone abnormal 
finding, having had consistent systematic pathology 
analysis performed for diagnostic purposes by the same 
expert cardiovascular pathologist (MNS), guided by no 
preconceived research hypothesis. The reported findings 
were only retrospectively reviewed and interpreted by the 
authors of this paper with the aim to characterise malig-
nant MVP. Our study found Barlow disease mitral valve 
characteristics and features of a distinct cardiomyopathy 
in MVP-related SCD.
Association of MVP with a cardiomyopathy7 was 
hypothesised soon after the description by Barlow of late 
systolic mitral regurgitation and ‘aneurysmal’ posterior 
leaflet protrusion within the left atrium12 in patients with 
systolic click. This hypothesis was based on the typical 
‘ballerina foot’ angiographic systolic appearance of the 
contrast-delineated left ventricular cavity in MVP, inter-
preted as being due to an abnormal myocardial contrac-
tion pattern.13
Non-invasive cardiac imaging findings enhanced suspi-
cion of potential association of MVP with a cardiomyop-
athy awaiting to be confirmed.8 14 Myocardial fibrosis on 
cardiac magnetic resonance was found to be associated 
with reduced global longitudinal strain and exercise 
capacity8 but not with the severity of mitral regurgitation 
in MVP14; therefore, a coexistent cardiomyopathy could 
explain the myocardial fibrosis. Furthermore, myocar-
dial fibrosis diagnosed on cardiac magnetic resonance, 
particularly papillary muscle fibrosis,15 was found to be 
associated with potentially malignant complex ventric-
ular arrhythmia14 15; therefore, a coexistent cardiomyop-
athy could explain malignant MVP. A higher incidence 
of arrhythmia at rest or on exertion was reported in SCD 
or out-of-hospital cardiac arrest cases due to malignant 
MVP.2 6 16 17
Electrocardiographic QT dispersion in MVP was found 
to be associated with the echocardiographic degree of 
MVP and anterior leaflet thickness18; however, it is also 
widely used as SCD risk marker in cardiomyopathy. This 
reported association of QT dispersion with more advanced 
mitral valve degeneration18 parallels our finding of asso-
ciation of myocardial fibrosis with more advanced mitral 
valve degeneration in SCD. Similarly, MVP-related SCD 
association with more advanced mitral valve degenera-
tion characterised by greater annulus circumference and 
greater length and thickness of leaflets has been previ-
ously reported by the group of Farb.1 The same group 
reported as well the existence of endocardial plaque in 
MVP-related SCD,1 although their study focused on the 
mitral valve morphology and not on the left ventricle.
SCD in degenerative mitral valve disease with severe 
mitral regurgitation16 can be easily explained as due to 
heart failure19; this is the case in a large published study 
of flail mitral valve leaflet,16 likely due to fibroelastic defi-
ciency.20 On the contrary, SCD in degenerative mitral 
valve disease with no chordal rupture and no significant 
mitral regurgitation2–4 6 is more difficult to explain; this 
is the case in the published study of malignant bileaflet 
MVP,6 likely due to Barlow disease.20 Detailed character-
isation of malignant MVP is needed to inform SCD risk 
stratification in MVP and select patients in need of ICD 
implantation for primary prevention.
Our study demonstrates MVP-related SCD associa-
tion with Barlow disease, regardless of mitral regurgita-
tion severity, more likely with left ventricular interstitial 
fibrosis and degeneration of myocytes suggestive of a 
distinct cardiomyopathy. These findings narrow down the 
spectrum of MVP-related SCD high-risk characteristics to 
Barlow disease with associated cardiomyopathy.
Papillary muscle traction in systole was described in 
Barlow disease,21 consequence of pronounced MVP, and 
this was thought to be arrhythmogenic and related with 
SCD. The posterior leaflet middle scallop is larger and 
more likely and more prominently prolapsing in all forms 
of MVP, including Barlow disease. The papillary muscle 
traction and the predominant posterior leaflet involve-
ment may explain the posterior wall and posterior papil-
lary muscle fibrosis in all our cases. The fibrosis found at 
postmortem or on late gadolinium enhancement cardiac 
magnetic resonance was interpreted as due to ‘myocar-
dial stretch by the prolapsing leaflet’ in a recent study of 
MVP-related SCD.22 However, the existence of ventricular 
fibrosis in areas not affected by traction or ‘stretch’ and, 
particularly, the existence of ventricular fibrosis within 
the right ventricle in our study, together with the coexis-
tent hypertrophy and degeneration of myocytes, suggest 
the existence of a cardiomyopathy.
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Our study found myocardial fibrosis on microscopic 
and not macroscopic pathology analysis. The fibrosis was 
extensive but focal rather than diffuse, always involving 
the posterior papillary muscle. Cardiac magnetic reso-
nance T1 mapping is thought to detect microscopic or 
diffuse fibrosis, while late gadolinium enhancement 
detects patchy macroscopic fibrosis. This may explain 
differences in prevalence of myocardial fibrosis detected 
with cardiac magnetic resonance in patients with complex 
ventricular arrhythmia14 compared with our study. Diffuse 
myocardial fibrosis on T1 mapping was found in 91% of 
cases, with only 41% having localised papillary muscle 
fibrosis on late gadolinium enhancement.14 Our findings 
could guide further studies of myocardial fibrosis with 
cardiac magnetic resonance, combining T1 mapping and 
late gadolinium enhancement for SCD risk stratification 
in MVP.
Our study had incomplete clinical data to corroborate 
with pathology findings, which is a limitation common 
for SCD pathology studies, due to the lack of previous 
diagnosis of disease in many SCD cases. Correlation of 
pathology and imaging findings would have been desir-
able; however, in cases having had an echocardiogram 
prior to SCD, the echocardiographic images were not 
available to the investigators for review.
Being based on pathology findings at autopsy 
performed for diagnostic rather than research purposes, 
our study does not include assessment for existence of 
mitral annular disjunction, anatomical variation present 
in MVP and also in the general population.23 24 The 
incidence of mitral annular disjunction is very high 
in MVP, and consequently also in MVP-related SCD or 
arrhythmia, having no use for SCD risk stratification. A 
recent pathology study25 reports mitral annular disjunc-
tion in MVP SCD cases but also in controls without MVP, 
differing though in measured length.
COnClusIOn
Malignant MVP is Barlow disease. MVP-related SCD is 
due to Barlow disease, which besides the typical mitral 
valve degeneration may comprise a distinct cardiomyo-
pathy. While further evidence is needed to underpin the 
selection of patients in need of ICD for primary preven-
tion, our results narrow down the spectrum of MVP-re-
lated SCD high-risk characteristics to Barlow disease with 
associated cardiomyopathy.
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